Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil plus corticosteroids versus placebo plus corticosteroids for newly diagnosed chronic graft-versus-host disease
CTR20242079Phase 3Active
- Sponsor
- Kadmon
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Kadmon. Started Aug 2024; status: active.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20242079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242079.